title: PLGA microspheres encapsulating siRNA.
abstract: The therapeutic use of small interfering RNA (siRNA) represents a new and powerful approach to suppress the expression of pathologically genes. However, biopharmaceutical drawbacks, such as short half-life, poor cellular uptake, and unspecific distribution into the body, hamper the development of siRNA-based therapeutics. Poly(lactide-co-glycolide), (PLGA) microspheres can be a useful tool to overcome these issues. siRNA can be encapsulated into the PLGA microspheres, which protects the loaded nucleic acid against the enzymatic degradation. Moreover, PLGA microspheres can be injected directly into the action site, where the siRNA can be released in controlled manner, thus avoiding the need of frequent invasive administrations. The complete biodegradability of PLGA to monomers easily metabolized by the body, and its approval by FDA and EMA for parenteral administration, assure the safety of this copolymer and do not require the removal of the device after the complete drug release. In chapter, a basic protocol for the preparation of PLGA microspheres encapsulating siRNA is described. This protocol is based on a double emulsion/solvent evaporation technique, a well known and easy to reproduce method. This specific protocol has been developed to encapsulate a siRNA anti-TNFα in PLGA microspheres, and it has been designed and optimized to achieve high siRNA encapsulation efficiency and slow siRNA release in vitro. However, it can be extended also to other siRNA as well as other RNA or DNA-based oligonucleotides (miRNA, antisense, decoy, etc.). Depending on the applications, chemical modifications of the backbone and site-specific modification within the siRNA sequences could be required.
authors.affiliation: Department of Pharmacy, Università degli Studi di Napoli Federico II, Via Domenico Montesano 49, 80131, Naples, Italy, gderosa@unina.it.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: De Rosa
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Salzano
mesh_terms: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004339:Drug Compounding / Q000295:instrumentation / Q000379:methods*; D004655:Emulsions; D005057:Eukaryotic Cells / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D019344:Lactic Acid / Q000138:chemical synthesis* / Q000378:metabolism; D008863:Microspheres; D011100:Polyglycolic Acid / Q000138:chemical synthesis* / Q000378:metabolism; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D034622:RNA Interference; D012333:RNA, Messenger / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D014835:Volatilization
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004655:Emulsions; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D014409:Tumor Necrosis Factor-alpha; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid